China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy-Reference-Cited by-同舟云学术

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Published:2019-06-20 Issue:1 Volume:39 Page:36
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Zhou Ming¹,Chen Xiaoyuan¹,Zhang Hong¹,Xia Lin¹,Tong Xin¹,Zou Limin¹,Hao Ruimin¹,Pan Jianhong¹,Zhao Xiao¹,Chen Dongmei¹,Song Yuanyuan¹,Qi Yueli¹,Tang Ling¹,Liu Zhifang¹,Gao Rong²,Shi Yuankai³,Yang Zhimin¹

Affiliation:

1. Medical Review Department 1, Center for Drug Evaluation; China National Medical Products Administration; No. 128 Jianguo Road, Chaoyang District Beijing 100022 P. R. China

2. Center for Drug Inspection; China National Medical Products Administration; Beijing 100037 P. R. China

3. Department of Medical Oncology; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing 100021 P. R. China

Funder

Chinese National Major Project for New Drug Innovation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s40880-019-0383-7.pdf

Reference21 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin.,2016

2. Cancer statistics in China, 2015;Chen;CA Cancer J Clin.,2016

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012